- Home
- ABVC
ABVC
ABVC BioPharma Inc.
as 12-18-2024 12:30pm EST
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 6.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 361.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.41 - $2.45 | Next Earning Date: | 11-14-2024 |
| Revenue: | $509,788 | Revenue Growth: | -31.04% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ABVC BioPharma Inc. News
ABVC Breaking Stock News: Dive into ABVC Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
GlobeNewswire
a month ago
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
GlobeNewswire
2 months ago
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
GlobeNewswire
4 months ago
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
NewMediaWire
5 months ago
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
NewMediaWire
6 months ago
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
NewMediaWire
6 months ago
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
NewMediaWire
6 months ago
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
Compare ABVC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABVC ABVC BioPharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.